ARFIP1

Across TCGA pan-cancer cohorts, ARFIP1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ARFIP1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ARFIP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARFIP1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, KIRC, and CHOL are the cancer types where ARFIP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARFIP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.779	<.001	9	view →
KIRC	All	III,IV	−0.345	<.001	6	view →
CHOL	Male	All	+1.663	<.001	5	view →
PAAD	All	All	+0.580	.014	4	view →
KICH	All	All	−0.532	<.001	4	view →
UCEC	All	All	−0.491	.008	4	view →
STAD	All	All	+0.404	.006	4	view →
COAD	All	All	−0.401	.006	4	view →
BRCA	All	II,III,IV	+0.301	<.001	4	view →
LUAD	All	All	+0.245	<.001	4	view →
ESCA	All	II,III,IV	+1.079	.011	2	view →
READ	Female	All	−0.504	.024	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ARFIP1–LIHC

Open the LIHC breakdown →